101,173 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Marshall Wace LLP

Marshall Wace LLP bought a new stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 101,173 shares of the medical research company's stock, valued at approximately $5,685,000. Marshall Wace LLP owned approximately 0.05% of Exact Sciences as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EXAS. Perigon Wealth Management LLC grew its stake in shares of Exact Sciences by 3.2% in the 4th quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company's stock valued at $474,000 after buying an additional 264 shares during the period. Sanctuary Advisors LLC grew its position in Exact Sciences by 2.0% in the fourth quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company's stock worth $763,000 after acquiring an additional 269 shares during the period. Daiwa Securities Group Inc. grew its position in Exact Sciences by 2.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 14,447 shares of the medical research company's stock worth $812,000 after acquiring an additional 300 shares during the period. Patten & Patten Inc. TN raised its position in Exact Sciences by 1.8% in the fourth quarter. Patten & Patten Inc. TN now owns 26,153 shares of the medical research company's stock valued at $1,470,000 after purchasing an additional 460 shares during the period. Finally, Forsta AP Fonden lifted its stake in shares of Exact Sciences by 1.3% in the 4th quarter. Forsta AP Fonden now owns 39,300 shares of the medical research company's stock valued at $2,208,000 after purchasing an additional 500 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Stock Down 0.1 %

Exact Sciences stock opened at $44.09 on Thursday. The stock has a market cap of $8.19 billion, a PE ratio of -7.92 and a beta of 1.14. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The stock's fifty day moving average is $45.50 and its two-hundred day moving average is $54.54. Exact Sciences Co. has a 1-year low of $39.97 and a 1-year high of $72.83.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.23. The business had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. On average, sell-side analysts expect that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on EXAS shares. William Blair reissued an "outperform" rating on shares of Exact Sciences in a research report on Thursday, February 20th. Benchmark reaffirmed a "buy" rating and set a $65.00 price objective on shares of Exact Sciences in a research report on Monday, January 13th. Guggenheim reiterated a "buy" rating and issued a $60.00 target price on shares of Exact Sciences in a report on Friday, April 11th. Scotiabank raised their price target on Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a research report on Monday, February 24th. Finally, Bank of America cut their price objective on Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $69.25.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.